Barinthus Biotherapeutics (STU:2AB) Additional Paid-In Capital: €342.80 Mil(As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:2AB Barinthus Biotherapeutics PLC STU:2AB
14 GF Score
Price €0.48
GF Value €0.93
! 1 Warning Sign
View Full Analysis

What is Barinthus Biotherapeutics Additional Paid-In Capital?

Barinthus Biotherapeutics STU:2AB 14 Additional Paid-In Capital is €342.80 Mil as of Jun. 2026. GuruFocus rates STU:2AB with a GF Score™ of 14/100 and a GF Value™ of €0.93. The stock has 1 warning sign investors should review.


Barinthus Biotherapeutics's quarterly additional paid-in capital increased from Dec. 2025 (€336.43 Mil) to Mar. 2026 (€341.24 Mil) and increased from Mar. 2026 (€341.24 Mil) to Jun. 2026 (€342.80 Mil).

Barinthus Biotherapeutics's annual additional paid-in capital increased from Dec. 2023 (€354.51 Mil) to Dec. 2024 (€375.77 Mil) but then declined from Dec. 2024 (€375.77 Mil) to Dec. 2025 (€336.43 Mil).

Barinthus Biotherapeutics Additional Paid-In Capital Related Terms

Barinthus Biotherapeutics Additional Paid-In Capital Historical Data

* Premium members only.

The historical data trend for Barinthus Biotherapeutics's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Barinthus Biotherapeutics Additional Paid-In Capital Chart

Barinthus Biotherapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Additional Paid-In Capital
Get a 7-Day Free Trial 326.66 358.25 354.51 375.77 336.43

Barinthus Biotherapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 341.31 335.05 336.43 341.24 342.80
STU:2AB
14GF Score
Barinthus Biotherapeutics PLC STU:2AB
Additional Paid-In Capital is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Barinthus Biotherapeutics Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)
What does a Additional Paid-In Capital of €342.80 Mil mean?
Barinthus Biotherapeutics (STU:2AB) has a Additional Paid-In Capital of €342.80 Mil as of Jun. 2026. Additional paid-in capital is the capital a company raises in excess of par value. View historical data on Barinthus Biotherapeutics and its competitors.
Is Barinthus Biotherapeutics' Additional Paid-In Capital too high?
Barinthus Biotherapeutics' current Additional Paid-In Capital is €342.80 Mil. Overall, Barinthus Biotherapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Barinthus Biotherapeutics' Additional Paid-In Capital compare to CRVO and ALGS?
Barinthus Biotherapeutics' Additional Paid-In Capital of €342.80 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Additional Paid-In Capital for a Biotechnology company?
A good Additional Paid-In Capital depends on the Biotechnology industry context. However, Additional Paid-In Capital should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Additional Paid-In Capital mean?
A high Additional Paid-In Capital can signal that a stock is expensive relative to its fundamentals. Additional paid-in capital is the capital a company raises in excess of par value. View historical data on Barinthus Biotherapeutics and its competitors. Barinthus Biotherapeutics's current Additional Paid-In Capital is €342.80 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Barinthus Biotherapeutics stock overvalued right now?
Barinthus Biotherapeutics (STU:2AB) has a current Additional Paid-In Capital of €342.80 Mil. The stock's GF Value™ is €0.93, compared to a current price of €0.48 — trading 48.4% below its estimated fair value. The current Additional Paid-In Capital is €342.80 Mil. Barinthus Biotherapeutics' overall GF Score™ is 14/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Additional Paid-In Capital calculated?
Additional Paid-In Capital is calculated from a company's financial statements. For Barinthus Biotherapeutics (STU:2AB), the current Additional Paid-In Capital is €342.80 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Barinthus Biotherapeutics (STU:2AB) Overvalued in 2026?

Based on GuruFocus' analysis, Barinthus Biotherapeutics stock appears to be undervalued. The current stock price of €0.48 is trading 48.4% below its estimated GF Value™ of €0.93.

Key valuation signals for STU:2AB:

  • Additional Paid-In Capital: €342.80 Mil
  • GF Value™: €0.93 vs. price of €0.48 (48.4% below fair value)
  • GF Score™: 14/100 with 1 warning sign

No single metric tells the full story. See the STU:2AB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Barinthus Biotherapeutics Business Description

Other Exchanges BRNS:USA
Address 20400 Century Boulevard, Suite 210, Germantown, MD, USA, 20874
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease. It is also developing VTP-300 for chronic hepatitis B using viral vector platform technologies, aimed at inducing disease-specific immune responses.
14GF Score

Get the complete analysis for STU:2AB

Additional Paid-In Capital is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.48
Price
€0.93
GF Value